nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—SLC22A1—hematologic cancer	0.156	0.503	CbGaD
Prazosin—ABCG2—hematologic cancer	0.109	0.351	CbGaD
Prazosin—ABCB1—hematologic cancer	0.0454	0.146	CbGaD
Prazosin—SLC22A3—Melphalan—hematologic cancer	0.0433	0.0936	CbGbCtD
Prazosin—ABCG2—Clofarabine—hematologic cancer	0.0228	0.0494	CbGbCtD
Prazosin—SLC22A2—Daunorubicin—hematologic cancer	0.0181	0.0392	CbGbCtD
Prazosin—ORM1—Imatinib—hematologic cancer	0.0168	0.0363	CbGbCtD
Prazosin—SLC22A2—Cytarabine—hematologic cancer	0.016	0.0346	CbGbCtD
Prazosin—SLC22A2—Cladribine—hematologic cancer	0.0151	0.0327	CbGbCtD
Prazosin—SLC22A3—Irinotecan—hematologic cancer	0.0146	0.0317	CbGbCtD
Prazosin—SLC22A1—Cytarabine—hematologic cancer	0.0139	0.03	CbGbCtD
Prazosin—SLC22A2—Imatinib—hematologic cancer	0.0139	0.03	CbGbCtD
Prazosin—CYP1A1—Methoxsalen—hematologic cancer	0.0136	0.0294	CbGbCtD
Prazosin—ABCG2—Daunorubicin—hematologic cancer	0.0134	0.0289	CbGbCtD
Prazosin—SLC22A1—Cladribine—hematologic cancer	0.0131	0.0284	CbGbCtD
Prazosin—CYP1A1—Bortezomib—hematologic cancer	0.0129	0.0279	CbGbCtD
Prazosin—SLC22A3—Vincristine—hematologic cancer	0.0128	0.0277	CbGbCtD
Prazosin—CYP1A1—Daunorubicin—hematologic cancer	0.0123	0.0267	CbGbCtD
Prazosin—SLC22A1—Imatinib—hematologic cancer	0.0121	0.0261	CbGbCtD
Prazosin—ABCG2—Teniposide—hematologic cancer	0.0116	0.0251	CbGbCtD
Prazosin—CYP1A1—Thalidomide—hematologic cancer	0.0112	0.0243	CbGbCtD
Prazosin—ABCG2—Cladribine—hematologic cancer	0.0111	0.0241	CbGbCtD
Prazosin—ABCG2—Imatinib—hematologic cancer	0.0102	0.0222	CbGbCtD
Prazosin—CYP1A1—Dacarbazine—hematologic cancer	0.00967	0.0209	CbGbCtD
Prazosin—ABCG2—Nilotinib—hematologic cancer	0.00931	0.0201	CbGbCtD
Prazosin—ABCG2—Dasatinib—hematologic cancer	0.00823	0.0178	CbGbCtD
Prazosin—ABCB1—Lenalidomide—hematologic cancer	0.00823	0.0178	CbGbCtD
Prazosin—ABCG2—Mitoxantrone—hematologic cancer	0.00813	0.0176	CbGbCtD
Prazosin—SLC22A2—Vinblastine—hematologic cancer	0.00771	0.0167	CbGbCtD
Prazosin—CYP1A1—Dasatinib—hematologic cancer	0.0076	0.0164	CbGbCtD
Prazosin—SLC22A2—Cisplatin—hematologic cancer	0.00707	0.0153	CbGbCtD
Prazosin—ABCG2—Irinotecan—hematologic cancer	0.0064	0.0138	CbGbCtD
Prazosin—ABCG2—Vincristine—hematologic cancer	0.00559	0.0121	CbGbCtD
Prazosin—ABCG2—Cisplatin—hematologic cancer	0.00522	0.0113	CbGbCtD
Prazosin—ABCG2—Etoposide—hematologic cancer	0.00513	0.0111	CbGbCtD
Prazosin—ABCB1—Daunorubicin—hematologic cancer	0.00482	0.0104	CbGbCtD
Prazosin—ABCB1—Alitretinoin—hematologic cancer	0.00472	0.0102	CbGbCtD
Prazosin—ABCG2—Dexamethasone—hematologic cancer	0.00421	0.00912	CbGbCtD
Prazosin—CYP1A1—Dexamethasone—hematologic cancer	0.00389	0.00842	CbGbCtD
Prazosin—ABCB1—Imatinib—hematologic cancer	0.00369	0.00799	CbGbCtD
Prazosin—ABCG2—Doxorubicin—hematologic cancer	0.0035	0.00756	CbGbCtD
Prazosin—ABCG2—Methotrexate—hematologic cancer	0.00339	0.00733	CbGbCtD
Prazosin—ABCB1—Nilotinib—hematologic cancer	0.00336	0.00726	CbGbCtD
Prazosin—ABCB1—Vinorelbine—hematologic cancer	0.00333	0.0072	CbGbCtD
Prazosin—ABCB1—Dasatinib—hematologic cancer	0.00297	0.00642	CbGbCtD
Prazosin—ABCB1—Mitoxantrone—hematologic cancer	0.00293	0.00634	CbGbCtD
Prazosin—ABCB1—Betamethasone—hematologic cancer	0.00261	0.00565	CbGbCtD
Prazosin—ABCB1—Gemcitabine—hematologic cancer	0.00259	0.0056	CbGbCtD
Prazosin—ABCB1—Prednisolone—hematologic cancer	0.00258	0.00558	CbGbCtD
Prazosin—ABCB1—Prednisone—hematologic cancer	0.00243	0.00527	CbGbCtD
Prazosin—ABCB1—Irinotecan—hematologic cancer	0.00231	0.00499	CbGbCtD
Prazosin—ABCB1—Vinblastine—hematologic cancer	0.00205	0.00444	CbGbCtD
Prazosin—ABCB1—Vincristine—hematologic cancer	0.00202	0.00436	CbGbCtD
Prazosin—ABCB1—Cisplatin—hematologic cancer	0.00188	0.00407	CbGbCtD
Prazosin—ABCB1—Etoposide—hematologic cancer	0.00185	0.004	CbGbCtD
Prazosin—ABCB1—Dexamethasone—hematologic cancer	0.00152	0.00329	CbGbCtD
Prazosin—MT3—lung—hematologic cancer	0.00135	0.071	CbGeAlD
Prazosin—MT3—testis—hematologic cancer	0.00127	0.067	CbGeAlD
Prazosin—KCNH7—testis—hematologic cancer	0.00127	0.067	CbGeAlD
Prazosin—ABCB1—Doxorubicin—hematologic cancer	0.00126	0.00273	CbGbCtD
Prazosin—ABCB1—Methotrexate—hematologic cancer	0.00122	0.00264	CbGbCtD
Prazosin—KCNH6—lung—hematologic cancer	0.00096	0.0506	CbGeAlD
Prazosin—MT3—lymph node—hematologic cancer	0.000922	0.0485	CbGeAlD
Prazosin—ORM1—hematopoietic system—hematologic cancer	0.000754	0.0397	CbGeAlD
Prazosin—SLC22A3—hematopoietic system—hematologic cancer	0.000661	0.0348	CbGeAlD
Prazosin—HTR1A—hematopoietic system—hematologic cancer	0.000571	0.0301	CbGeAlD
Prazosin—ADRA1A—hematopoietic system—hematologic cancer	0.000526	0.0277	CbGeAlD
Prazosin—KCNH2—hematopoietic system—hematologic cancer	0.000508	0.0268	CbGeAlD
Prazosin—SLC22A3—gonad—hematologic cancer	0.000502	0.0264	CbGeAlD
Prazosin—ORM1—blood—hematologic cancer	0.0005	0.0263	CbGeAlD
Prazosin—ORM1—bone marrow—hematologic cancer	0.000484	0.0255	CbGeAlD
Prazosin—SLC22A1—blood—hematologic cancer	0.000458	0.0241	CbGeAlD
Prazosin—ORM1—lung—hematologic cancer	0.000438	0.0231	CbGeAlD
Prazosin—CYP1A1—hematopoietic system—hematologic cancer	0.000429	0.0226	CbGeAlD
Prazosin—ADRA2A—hematopoietic system—hematologic cancer	0.0004	0.0211	CbGeAlD
Prazosin—SLC22A3—lung—hematologic cancer	0.000384	0.0202	CbGeAlD
Prazosin—SLC22A3—testis—hematologic cancer	0.000362	0.0191	CbGeAlD
Prazosin—ADRA1A—blood—hematologic cancer	0.000349	0.0184	CbGeAlD
Prazosin—KCNH2—blood—hematologic cancer	0.000337	0.0177	CbGeAlD
Prazosin—KCNH2—bone marrow—hematologic cancer	0.000326	0.0172	CbGeAlD
Prazosin—ADRA2A—gonad—hematologic cancer	0.000304	0.016	CbGeAlD
Prazosin—ORM1—lymph node—hematologic cancer	0.0003	0.0158	CbGeAlD
Prazosin—ABCG2—blood—hematologic cancer	0.0003	0.0158	CbGeAlD
Prazosin—ABCG2—bone marrow—hematologic cancer	0.00029	0.0153	CbGeAlD
Prazosin—CYP1A1—blood—hematologic cancer	0.000284	0.015	CbGeAlD
Prazosin—KCNH2—testis—hematologic cancer	0.000278	0.0147	CbGeAlD
Prazosin—ADRA2A—blood—hematologic cancer	0.000265	0.014	CbGeAlD
Prazosin—ABCG2—lung—hematologic cancer	0.000263	0.0138	CbGeAlD
Prazosin—SLC22A3—lymph node—hematologic cancer	0.000262	0.0138	CbGeAlD
Prazosin—CYP1A1—lung—hematologic cancer	0.000249	0.0131	CbGeAlD
Prazosin—ABCG2—testis—hematologic cancer	0.000248	0.013	CbGeAlD
Prazosin—ADRA2A—lung—hematologic cancer	0.000232	0.0122	CbGeAlD
Prazosin—ABCB1—hematopoietic system—hematologic cancer	0.000223	0.0117	CbGeAlD
Prazosin—ADRA2A—testis—hematologic cancer	0.000219	0.0115	CbGeAlD
Prazosin—KCNH2—lymph node—hematologic cancer	0.000202	0.0106	CbGeAlD
Prazosin—ABCG2—lymph node—hematologic cancer	0.00018	0.00945	CbGeAlD
Prazosin—CYP1A1—lymph node—hematologic cancer	0.00017	0.00898	CbGeAlD
Prazosin—ABCB1—gonad—hematologic cancer	0.000169	0.00892	CbGeAlD
Prazosin—ADRA2A—lymph node—hematologic cancer	0.000159	0.00837	CbGeAlD
Prazosin—ABCB1—blood—hematologic cancer	0.000148	0.00778	CbGeAlD
Prazosin—ABCB1—bone marrow—hematologic cancer	0.000143	0.00752	CbGeAlD
Prazosin—ABCB1—lung—hematologic cancer	0.000129	0.00682	CbGeAlD
Prazosin—ABCB1—testis—hematologic cancer	0.000122	0.00643	CbGeAlD
Prazosin—Terazosin—ABCB1—hematologic cancer	8.9e-05	0.573	CrCbGaD
Prazosin—ABCB1—lymph node—hematologic cancer	8.86e-05	0.00466	CbGeAlD
Prazosin—Doxazosin—ABCB1—hematologic cancer	6.62e-05	0.427	CrCbGaD
Prazosin—Rash—Alitretinoin—hematologic cancer	4.4e-05	0.000327	CcSEcCtD
Prazosin—Dermatitis—Alitretinoin—hematologic cancer	4.4e-05	0.000327	CcSEcCtD
Prazosin—Vomiting—Ifosfamide—hematologic cancer	4.38e-05	0.000326	CcSEcCtD
Prazosin—Hypersensitivity—Cisplatin—hematologic cancer	4.38e-05	0.000326	CcSEcCtD
Prazosin—Tachycardia—Betamethasone—hematologic cancer	4.37e-05	0.000326	CcSEcCtD
Prazosin—Tachycardia—Dexamethasone—hematologic cancer	4.37e-05	0.000326	CcSEcCtD
Prazosin—Bradycardia—Epirubicin—hematologic cancer	4.37e-05	0.000326	CcSEcCtD
Prazosin—Headache—Alitretinoin—hematologic cancer	4.37e-05	0.000325	CcSEcCtD
Prazosin—Diarrhoea—Gemcitabine—hematologic cancer	4.36e-05	0.000325	CcSEcCtD
Prazosin—Nausea—Thalidomide—hematologic cancer	4.36e-05	0.000324	CcSEcCtD
Prazosin—Rash—Ifosfamide—hematologic cancer	4.35e-05	0.000324	CcSEcCtD
Prazosin—Dermatitis—Ifosfamide—hematologic cancer	4.34e-05	0.000323	CcSEcCtD
Prazosin—Hyperhidrosis—Dexamethasone—hematologic cancer	4.33e-05	0.000323	CcSEcCtD
Prazosin—Hyperhidrosis—Betamethasone—hematologic cancer	4.33e-05	0.000323	CcSEcCtD
Prazosin—Dizziness—Irinotecan—hematologic cancer	4.33e-05	0.000322	CcSEcCtD
Prazosin—Urticaria—Etoposide—hematologic cancer	4.33e-05	0.000322	CcSEcCtD
Prazosin—Malaise—Prednisone—hematologic cancer	4.31e-05	0.000321	CcSEcCtD
Prazosin—Body temperature increased—Etoposide—hematologic cancer	4.31e-05	0.00032	CcSEcCtD
Prazosin—Vertigo—Prednisone—hematologic cancer	4.3e-05	0.00032	CcSEcCtD
Prazosin—Syncope—Prednisone—hematologic cancer	4.29e-05	0.000319	CcSEcCtD
Prazosin—Tinnitus—Methotrexate—hematologic cancer	4.28e-05	0.000319	CcSEcCtD
Prazosin—Vomiting—Vincristine—hematologic cancer	4.27e-05	0.000318	CcSEcCtD
Prazosin—Urticaria—Prednisolone—hematologic cancer	4.27e-05	0.000318	CcSEcCtD
Prazosin—Asthenia—Cisplatin—hematologic cancer	4.27e-05	0.000317	CcSEcCtD
Prazosin—Fatigue—Triamcinolone—hematologic cancer	4.26e-05	0.000317	CcSEcCtD
Prazosin—Rash—Vincristine—hematologic cancer	4.24e-05	0.000316	CcSEcCtD
Prazosin—Dermatitis—Vincristine—hematologic cancer	4.24e-05	0.000315	CcSEcCtD
Prazosin—Pain—Triamcinolone—hematologic cancer	4.22e-05	0.000314	CcSEcCtD
Prazosin—Headache—Vincristine—hematologic cancer	4.21e-05	0.000313	CcSEcCtD
Prazosin—Loss of consciousness—Prednisone—hematologic cancer	4.2e-05	0.000313	CcSEcCtD
Prazosin—Nausea—Carmustine—hematologic cancer	4.18e-05	0.000311	CcSEcCtD
Prazosin—Epistaxis—Doxorubicin—hematologic cancer	4.18e-05	0.000311	CcSEcCtD
Prazosin—Vomiting—Mitoxantrone—hematologic cancer	4.16e-05	0.00031	CcSEcCtD
Prazosin—Vomiting—Irinotecan—hematologic cancer	4.16e-05	0.00031	CcSEcCtD
Prazosin—Nausea—Alitretinoin—hematologic cancer	4.14e-05	0.000308	CcSEcCtD
Prazosin—Rash—Mitoxantrone—hematologic cancer	4.13e-05	0.000307	CcSEcCtD
Prazosin—Rash—Irinotecan—hematologic cancer	4.13e-05	0.000307	CcSEcCtD
Prazosin—Dermatitis—Mitoxantrone—hematologic cancer	4.12e-05	0.000307	CcSEcCtD
Prazosin—Dermatitis—Irinotecan—hematologic cancer	4.12e-05	0.000307	CcSEcCtD
Prazosin—Headache—Mitoxantrone—hematologic cancer	4.1e-05	0.000305	CcSEcCtD
Prazosin—Headache—Irinotecan—hematologic cancer	4.1e-05	0.000305	CcSEcCtD
Prazosin—Nausea—Ifosfamide—hematologic cancer	4.1e-05	0.000305	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.08e-05	0.000304	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.08e-05	0.000304	CcSEcCtD
Prazosin—Arthralgia—Prednisone—hematologic cancer	4.07e-05	0.000303	CcSEcCtD
Prazosin—Feeling abnormal—Triamcinolone—hematologic cancer	4.07e-05	0.000303	CcSEcCtD
Prazosin—Diarrhoea—Cisplatin—hematologic cancer	4.07e-05	0.000303	CcSEcCtD
Prazosin—Alopecia—Methotrexate—hematologic cancer	4.06e-05	0.000302	CcSEcCtD
Prazosin—Vomiting—Gemcitabine—hematologic cancer	4.06e-05	0.000302	CcSEcCtD
Prazosin—Insomnia—Dexamethasone—hematologic cancer	4.05e-05	0.000302	CcSEcCtD
Prazosin—Insomnia—Betamethasone—hematologic cancer	4.05e-05	0.000302	CcSEcCtD
Prazosin—Bradycardia—Doxorubicin—hematologic cancer	4.05e-05	0.000301	CcSEcCtD
Prazosin—Paraesthesia—Dexamethasone—hematologic cancer	4.02e-05	0.0003	CcSEcCtD
Prazosin—Paraesthesia—Betamethasone—hematologic cancer	4.02e-05	0.0003	CcSEcCtD
Prazosin—Discomfort—Prednisone—hematologic cancer	4.02e-05	0.000299	CcSEcCtD
Prazosin—Rash—Gemcitabine—hematologic cancer	4.02e-05	0.000299	CcSEcCtD
Prazosin—Dermatitis—Gemcitabine—hematologic cancer	4.02e-05	0.000299	CcSEcCtD
Prazosin—Hypersensitivity—Etoposide—hematologic cancer	4.01e-05	0.000299	CcSEcCtD
Prazosin—Tinnitus—Epirubicin—hematologic cancer	4.01e-05	0.000298	CcSEcCtD
Prazosin—Headache—Gemcitabine—hematologic cancer	4e-05	0.000297	CcSEcCtD
Prazosin—Nausea—Vincristine—hematologic cancer	3.99e-05	0.000297	CcSEcCtD
Prazosin—Flushing—Epirubicin—hematologic cancer	3.99e-05	0.000297	CcSEcCtD
Prazosin—Hypersensitivity—Prednisolone—hematologic cancer	3.96e-05	0.000295	CcSEcCtD
Prazosin—Urticaria—Triamcinolone—hematologic cancer	3.92e-05	0.000292	CcSEcCtD
Prazosin—Asthenia—Etoposide—hematologic cancer	3.91e-05	0.000291	CcSEcCtD
Prazosin—Body temperature increased—Triamcinolone—hematologic cancer	3.91e-05	0.000291	CcSEcCtD
Prazosin—Oedema—Prednisone—hematologic cancer	3.9e-05	0.000291	CcSEcCtD
Prazosin—Nausea—Mitoxantrone—hematologic cancer	3.89e-05	0.000289	CcSEcCtD
Prazosin—Nausea—Irinotecan—hematologic cancer	3.89e-05	0.000289	CcSEcCtD
Prazosin—Fatigue—Dexamethasone—hematologic cancer	3.86e-05	0.000288	CcSEcCtD
Prazosin—Fatigue—Betamethasone—hematologic cancer	3.86e-05	0.000288	CcSEcCtD
Prazosin—Pruritus—Etoposide—hematologic cancer	3.85e-05	0.000287	CcSEcCtD
Prazosin—Shock—Prednisone—hematologic cancer	3.84e-05	0.000286	CcSEcCtD
Prazosin—Pain—Dexamethasone—hematologic cancer	3.83e-05	0.000285	CcSEcCtD
Prazosin—Pain—Betamethasone—hematologic cancer	3.83e-05	0.000285	CcSEcCtD
Prazosin—Tachycardia—Prednisone—hematologic cancer	3.81e-05	0.000284	CcSEcCtD
Prazosin—Alopecia—Epirubicin—hematologic cancer	3.8e-05	0.000283	CcSEcCtD
Prazosin—Nausea—Gemcitabine—hematologic cancer	3.79e-05	0.000282	CcSEcCtD
Prazosin—Vomiting—Cisplatin—hematologic cancer	3.78e-05	0.000281	CcSEcCtD
Prazosin—Hyperhidrosis—Prednisone—hematologic cancer	3.77e-05	0.000281	CcSEcCtD
Prazosin—Vision blurred—Methotrexate—hematologic cancer	3.77e-05	0.00028	CcSEcCtD
Prazosin—Rash—Cisplatin—hematologic cancer	3.75e-05	0.000279	CcSEcCtD
Prazosin—Dermatitis—Cisplatin—hematologic cancer	3.74e-05	0.000279	CcSEcCtD
Prazosin—Diarrhoea—Etoposide—hematologic cancer	3.73e-05	0.000277	CcSEcCtD
Prazosin—Ill-defined disorder—Methotrexate—hematologic cancer	3.71e-05	0.000276	CcSEcCtD
Prazosin—Tinnitus—Doxorubicin—hematologic cancer	3.71e-05	0.000276	CcSEcCtD
Prazosin—Feeling abnormal—Dexamethasone—hematologic cancer	3.69e-05	0.000275	CcSEcCtD
Prazosin—Feeling abnormal—Betamethasone—hematologic cancer	3.69e-05	0.000275	CcSEcCtD
Prazosin—Flushing—Doxorubicin—hematologic cancer	3.69e-05	0.000275	CcSEcCtD
Prazosin—Tension—Epirubicin—hematologic cancer	3.67e-05	0.000273	CcSEcCtD
Prazosin—Hypersensitivity—Triamcinolone—hematologic cancer	3.64e-05	0.000271	CcSEcCtD
Prazosin—Nervousness—Epirubicin—hematologic cancer	3.63e-05	0.00027	CcSEcCtD
Prazosin—Malaise—Methotrexate—hematologic cancer	3.6e-05	0.000268	CcSEcCtD
Prazosin—Dizziness—Etoposide—hematologic cancer	3.6e-05	0.000268	CcSEcCtD
Prazosin—Vertigo—Methotrexate—hematologic cancer	3.59e-05	0.000267	CcSEcCtD
Prazosin—Urticaria—Dexamethasone—hematologic cancer	3.56e-05	0.000265	CcSEcCtD
Prazosin—Urticaria—Betamethasone—hematologic cancer	3.56e-05	0.000265	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.56e-05	0.000265	CcSEcCtD
Prazosin—Dizziness—Prednisolone—hematologic cancer	3.55e-05	0.000264	CcSEcCtD
Prazosin—Asthenia—Triamcinolone—hematologic cancer	3.54e-05	0.000264	CcSEcCtD
Prazosin—Body temperature increased—Dexamethasone—hematologic cancer	3.54e-05	0.000264	CcSEcCtD
Prazosin—Body temperature increased—Betamethasone—hematologic cancer	3.54e-05	0.000264	CcSEcCtD
Prazosin—Nausea—Cisplatin—hematologic cancer	3.53e-05	0.000263	CcSEcCtD
Prazosin—Insomnia—Prednisone—hematologic cancer	3.53e-05	0.000263	CcSEcCtD
Prazosin—Vision blurred—Epirubicin—hematologic cancer	3.53e-05	0.000262	CcSEcCtD
Prazosin—Alopecia—Doxorubicin—hematologic cancer	3.51e-05	0.000261	CcSEcCtD
Prazosin—Paraesthesia—Prednisone—hematologic cancer	3.51e-05	0.000261	CcSEcCtD
Prazosin—Pruritus—Triamcinolone—hematologic cancer	3.5e-05	0.00026	CcSEcCtD
Prazosin—Ill-defined disorder—Epirubicin—hematologic cancer	3.47e-05	0.000258	CcSEcCtD
Prazosin—Vomiting—Etoposide—hematologic cancer	3.46e-05	0.000258	CcSEcCtD
Prazosin—Rash—Etoposide—hematologic cancer	3.43e-05	0.000256	CcSEcCtD
Prazosin—Dermatitis—Etoposide—hematologic cancer	3.43e-05	0.000255	CcSEcCtD
Prazosin—Headache—Etoposide—hematologic cancer	3.41e-05	0.000254	CcSEcCtD
Prazosin—Arthralgia—Methotrexate—hematologic cancer	3.4e-05	0.000253	CcSEcCtD
Prazosin—Tension—Doxorubicin—hematologic cancer	3.4e-05	0.000253	CcSEcCtD
Prazosin—Rash—Prednisolone—hematologic cancer	3.39e-05	0.000252	CcSEcCtD
Prazosin—Dermatitis—Prednisolone—hematologic cancer	3.38e-05	0.000252	CcSEcCtD
Prazosin—Malaise—Epirubicin—hematologic cancer	3.37e-05	0.000251	CcSEcCtD
Prazosin—Fatigue—Prednisone—hematologic cancer	3.37e-05	0.00025	CcSEcCtD
Prazosin—Headache—Prednisolone—hematologic cancer	3.37e-05	0.00025	CcSEcCtD
Prazosin—Discomfort—Methotrexate—hematologic cancer	3.36e-05	0.00025	CcSEcCtD
Prazosin—Nervousness—Doxorubicin—hematologic cancer	3.36e-05	0.00025	CcSEcCtD
Prazosin—Vertigo—Epirubicin—hematologic cancer	3.36e-05	0.00025	CcSEcCtD
Prazosin—Syncope—Epirubicin—hematologic cancer	3.35e-05	0.00025	CcSEcCtD
Prazosin—Constipation—Prednisone—hematologic cancer	3.34e-05	0.000248	CcSEcCtD
Prazosin—Palpitations—Epirubicin—hematologic cancer	3.31e-05	0.000246	CcSEcCtD
Prazosin—Loss of consciousness—Epirubicin—hematologic cancer	3.29e-05	0.000245	CcSEcCtD
Prazosin—Dizziness—Triamcinolone—hematologic cancer	3.27e-05	0.000243	CcSEcCtD
Prazosin—Vision blurred—Doxorubicin—hematologic cancer	3.26e-05	0.000243	CcSEcCtD
Prazosin—Nausea—Etoposide—hematologic cancer	3.24e-05	0.000241	CcSEcCtD
Prazosin—Feeling abnormal—Prednisone—hematologic cancer	3.22e-05	0.000239	CcSEcCtD
Prazosin—Asthenia—Dexamethasone—hematologic cancer	3.22e-05	0.000239	CcSEcCtD
Prazosin—Asthenia—Betamethasone—hematologic cancer	3.22e-05	0.000239	CcSEcCtD
Prazosin—Ill-defined disorder—Doxorubicin—hematologic cancer	3.21e-05	0.000239	CcSEcCtD
Prazosin—Nausea—Prednisolone—hematologic cancer	3.19e-05	0.000237	CcSEcCtD
Prazosin—Arthralgia—Epirubicin—hematologic cancer	3.18e-05	0.000237	CcSEcCtD
Prazosin—Pruritus—Betamethasone—hematologic cancer	3.17e-05	0.000236	CcSEcCtD
Prazosin—Pruritus—Dexamethasone—hematologic cancer	3.17e-05	0.000236	CcSEcCtD
Prazosin—Hyperhidrosis—Methotrexate—hematologic cancer	3.15e-05	0.000235	CcSEcCtD
Prazosin—Discomfort—Epirubicin—hematologic cancer	3.15e-05	0.000234	CcSEcCtD
Prazosin—Vomiting—Triamcinolone—hematologic cancer	3.14e-05	0.000234	CcSEcCtD
Prazosin—Malaise—Doxorubicin—hematologic cancer	3.12e-05	0.000232	CcSEcCtD
Prazosin—Rash—Triamcinolone—hematologic cancer	3.11e-05	0.000232	CcSEcCtD
Prazosin—Dry mouth—Epirubicin—hematologic cancer	3.11e-05	0.000232	CcSEcCtD
Prazosin—Dermatitis—Triamcinolone—hematologic cancer	3.11e-05	0.000232	CcSEcCtD
Prazosin—Vertigo—Doxorubicin—hematologic cancer	3.11e-05	0.000231	CcSEcCtD
Prazosin—Syncope—Doxorubicin—hematologic cancer	3.1e-05	0.000231	CcSEcCtD
Prazosin—Urticaria—Prednisone—hematologic cancer	3.1e-05	0.000231	CcSEcCtD
Prazosin—Headache—Triamcinolone—hematologic cancer	3.09e-05	0.00023	CcSEcCtD
Prazosin—Body temperature increased—Prednisone—hematologic cancer	3.09e-05	0.00023	CcSEcCtD
Prazosin—Diarrhoea—Betamethasone—hematologic cancer	3.07e-05	0.000228	CcSEcCtD
Prazosin—Diarrhoea—Dexamethasone—hematologic cancer	3.07e-05	0.000228	CcSEcCtD
Prazosin—Palpitations—Doxorubicin—hematologic cancer	3.06e-05	0.000228	CcSEcCtD
Prazosin—Oedema—Epirubicin—hematologic cancer	3.05e-05	0.000227	CcSEcCtD
Prazosin—Loss of consciousness—Doxorubicin—hematologic cancer	3.04e-05	0.000226	CcSEcCtD
Prazosin—Shock—Epirubicin—hematologic cancer	3e-05	0.000224	CcSEcCtD
Prazosin—Tachycardia—Epirubicin—hematologic cancer	2.98e-05	0.000222	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.97e-05	0.000221	CcSEcCtD
Prazosin—Dizziness—Dexamethasone—hematologic cancer	2.96e-05	0.000221	CcSEcCtD
Prazosin—Dizziness—Betamethasone—hematologic cancer	2.96e-05	0.000221	CcSEcCtD
Prazosin—Hyperhidrosis—Epirubicin—hematologic cancer	2.95e-05	0.00022	CcSEcCtD
Prazosin—Insomnia—Methotrexate—hematologic cancer	2.95e-05	0.00022	CcSEcCtD
Prazosin—Arthralgia—Doxorubicin—hematologic cancer	2.95e-05	0.000219	CcSEcCtD
Prazosin—Nausea—Triamcinolone—hematologic cancer	2.93e-05	0.000218	CcSEcCtD
Prazosin—Paraesthesia—Methotrexate—hematologic cancer	2.93e-05	0.000218	CcSEcCtD
Prazosin—Discomfort—Doxorubicin—hematologic cancer	2.91e-05	0.000217	CcSEcCtD
Prazosin—Dyspnoea—Methotrexate—hematologic cancer	2.91e-05	0.000216	CcSEcCtD
Prazosin—Somnolence—Methotrexate—hematologic cancer	2.9e-05	0.000216	CcSEcCtD
Prazosin—Dry mouth—Doxorubicin—hematologic cancer	2.88e-05	0.000214	CcSEcCtD
Prazosin—Hypersensitivity—Prednisone—hematologic cancer	2.88e-05	0.000214	CcSEcCtD
Prazosin—Vomiting—Dexamethasone—hematologic cancer	2.85e-05	0.000212	CcSEcCtD
Prazosin—Vomiting—Betamethasone—hematologic cancer	2.85e-05	0.000212	CcSEcCtD
Prazosin—Rash—Dexamethasone—hematologic cancer	2.83e-05	0.00021	CcSEcCtD
Prazosin—Rash—Betamethasone—hematologic cancer	2.83e-05	0.00021	CcSEcCtD
Prazosin—Oedema—Doxorubicin—hematologic cancer	2.82e-05	0.00021	CcSEcCtD
Prazosin—Dermatitis—Betamethasone—hematologic cancer	2.82e-05	0.00021	CcSEcCtD
Prazosin—Dermatitis—Dexamethasone—hematologic cancer	2.82e-05	0.00021	CcSEcCtD
Prazosin—Fatigue—Methotrexate—hematologic cancer	2.81e-05	0.000209	CcSEcCtD
Prazosin—Headache—Dexamethasone—hematologic cancer	2.81e-05	0.000209	CcSEcCtD
Prazosin—Headache—Betamethasone—hematologic cancer	2.81e-05	0.000209	CcSEcCtD
Prazosin—Asthenia—Prednisone—hematologic cancer	2.8e-05	0.000208	CcSEcCtD
Prazosin—Pain—Methotrexate—hematologic cancer	2.79e-05	0.000208	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.78e-05	0.000207	CcSEcCtD
Prazosin—Shock—Doxorubicin—hematologic cancer	2.78e-05	0.000207	CcSEcCtD
Prazosin—Pruritus—Prednisone—hematologic cancer	2.76e-05	0.000206	CcSEcCtD
Prazosin—Insomnia—Epirubicin—hematologic cancer	2.76e-05	0.000206	CcSEcCtD
Prazosin—Tachycardia—Doxorubicin—hematologic cancer	2.76e-05	0.000205	CcSEcCtD
Prazosin—Paraesthesia—Epirubicin—hematologic cancer	2.74e-05	0.000204	CcSEcCtD
Prazosin—Hyperhidrosis—Doxorubicin—hematologic cancer	2.73e-05	0.000203	CcSEcCtD
Prazosin—Dyspnoea—Epirubicin—hematologic cancer	2.72e-05	0.000203	CcSEcCtD
Prazosin—Somnolence—Epirubicin—hematologic cancer	2.71e-05	0.000202	CcSEcCtD
Prazosin—Feeling abnormal—Methotrexate—hematologic cancer	2.69e-05	0.0002	CcSEcCtD
Prazosin—Diarrhoea—Prednisone—hematologic cancer	2.67e-05	0.000199	CcSEcCtD
Prazosin—Nausea—Dexamethasone—hematologic cancer	2.66e-05	0.000198	CcSEcCtD
Prazosin—Nausea—Betamethasone—hematologic cancer	2.66e-05	0.000198	CcSEcCtD
Prazosin—Fatigue—Epirubicin—hematologic cancer	2.63e-05	0.000196	CcSEcCtD
Prazosin—Pain—Epirubicin—hematologic cancer	2.61e-05	0.000194	CcSEcCtD
Prazosin—Constipation—Epirubicin—hematologic cancer	2.61e-05	0.000194	CcSEcCtD
Prazosin—Urticaria—Methotrexate—hematologic cancer	2.59e-05	0.000193	CcSEcCtD
Prazosin—Dizziness—Prednisone—hematologic cancer	2.58e-05	0.000192	CcSEcCtD
Prazosin—Body temperature increased—Methotrexate—hematologic cancer	2.58e-05	0.000192	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.57e-05	0.000192	CcSEcCtD
Prazosin—Insomnia—Doxorubicin—hematologic cancer	2.55e-05	0.00019	CcSEcCtD
Prazosin—Paraesthesia—Doxorubicin—hematologic cancer	2.54e-05	0.000189	CcSEcCtD
Prazosin—Dyspnoea—Doxorubicin—hematologic cancer	2.52e-05	0.000187	CcSEcCtD
Prazosin—Feeling abnormal—Epirubicin—hematologic cancer	2.52e-05	0.000187	CcSEcCtD
Prazosin—Somnolence—Doxorubicin—hematologic cancer	2.51e-05	0.000187	CcSEcCtD
Prazosin—Vomiting—Prednisone—hematologic cancer	2.48e-05	0.000185	CcSEcCtD
Prazosin—Rash—Prednisone—hematologic cancer	2.46e-05	0.000183	CcSEcCtD
Prazosin—Dermatitis—Prednisone—hematologic cancer	2.46e-05	0.000183	CcSEcCtD
Prazosin—Headache—Prednisone—hematologic cancer	2.45e-05	0.000182	CcSEcCtD
Prazosin—Fatigue—Doxorubicin—hematologic cancer	2.44e-05	0.000181	CcSEcCtD
Prazosin—Urticaria—Epirubicin—hematologic cancer	2.43e-05	0.000181	CcSEcCtD
Prazosin—Constipation—Doxorubicin—hematologic cancer	2.42e-05	0.00018	CcSEcCtD
Prazosin—Pain—Doxorubicin—hematologic cancer	2.42e-05	0.00018	CcSEcCtD
Prazosin—Body temperature increased—Epirubicin—hematologic cancer	2.41e-05	0.00018	CcSEcCtD
Prazosin—Hypersensitivity—Methotrexate—hematologic cancer	2.4e-05	0.000179	CcSEcCtD
Prazosin—Asthenia—Methotrexate—hematologic cancer	2.34e-05	0.000174	CcSEcCtD
Prazosin—Feeling abnormal—Doxorubicin—hematologic cancer	2.33e-05	0.000173	CcSEcCtD
Prazosin—Nausea—Prednisone—hematologic cancer	2.32e-05	0.000173	CcSEcCtD
Prazosin—Pruritus—Methotrexate—hematologic cancer	2.31e-05	0.000172	CcSEcCtD
Prazosin—Hypersensitivity—Epirubicin—hematologic cancer	2.25e-05	0.000167	CcSEcCtD
Prazosin—Urticaria—Doxorubicin—hematologic cancer	2.24e-05	0.000167	CcSEcCtD
Prazosin—Body temperature increased—Doxorubicin—hematologic cancer	2.23e-05	0.000166	CcSEcCtD
Prazosin—Diarrhoea—Methotrexate—hematologic cancer	2.23e-05	0.000166	CcSEcCtD
Prazosin—Asthenia—Epirubicin—hematologic cancer	2.19e-05	0.000163	CcSEcCtD
Prazosin—Pruritus—Epirubicin—hematologic cancer	2.16e-05	0.000161	CcSEcCtD
Prazosin—Dizziness—Methotrexate—hematologic cancer	2.16e-05	0.000161	CcSEcCtD
Prazosin—Diarrhoea—Epirubicin—hematologic cancer	2.09e-05	0.000155	CcSEcCtD
Prazosin—Hypersensitivity—Doxorubicin—hematologic cancer	2.08e-05	0.000155	CcSEcCtD
Prazosin—Vomiting—Methotrexate—hematologic cancer	2.07e-05	0.000154	CcSEcCtD
Prazosin—Rash—Methotrexate—hematologic cancer	2.06e-05	0.000153	CcSEcCtD
Prazosin—Dermatitis—Methotrexate—hematologic cancer	2.06e-05	0.000153	CcSEcCtD
Prazosin—Headache—Methotrexate—hematologic cancer	2.04e-05	0.000152	CcSEcCtD
Prazosin—Asthenia—Doxorubicin—hematologic cancer	2.03e-05	0.000151	CcSEcCtD
Prazosin—Dizziness—Epirubicin—hematologic cancer	2.02e-05	0.00015	CcSEcCtD
Prazosin—Pruritus—Doxorubicin—hematologic cancer	2e-05	0.000149	CcSEcCtD
Prazosin—Vomiting—Epirubicin—hematologic cancer	1.94e-05	0.000144	CcSEcCtD
Prazosin—Nausea—Methotrexate—hematologic cancer	1.94e-05	0.000144	CcSEcCtD
Prazosin—Diarrhoea—Doxorubicin—hematologic cancer	1.93e-05	0.000144	CcSEcCtD
Prazosin—Rash—Epirubicin—hematologic cancer	1.92e-05	0.000143	CcSEcCtD
Prazosin—Dermatitis—Epirubicin—hematologic cancer	1.92e-05	0.000143	CcSEcCtD
Prazosin—Headache—Epirubicin—hematologic cancer	1.91e-05	0.000142	CcSEcCtD
Prazosin—Dizziness—Doxorubicin—hematologic cancer	1.87e-05	0.000139	CcSEcCtD
Prazosin—Nausea—Epirubicin—hematologic cancer	1.81e-05	0.000135	CcSEcCtD
Prazosin—Vomiting—Doxorubicin—hematologic cancer	1.8e-05	0.000134	CcSEcCtD
Prazosin—Rash—Doxorubicin—hematologic cancer	1.78e-05	0.000133	CcSEcCtD
Prazosin—Dermatitis—Doxorubicin—hematologic cancer	1.78e-05	0.000132	CcSEcCtD
Prazosin—Headache—Doxorubicin—hematologic cancer	1.77e-05	0.000132	CcSEcCtD
Prazosin—Nausea—Doxorubicin—hematologic cancer	1.68e-05	0.000125	CcSEcCtD
Prazosin—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	1.73e-06	2.35e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTEN—hematologic cancer	1.72e-06	2.33e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	1.72e-06	2.33e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—STAT3—hematologic cancer	1.72e-06	2.32e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	1.71e-06	2.32e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	1.71e-06	2.32e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NRAS—hematologic cancer	1.71e-06	2.32e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.71e-06	2.31e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	1.71e-06	2.31e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	1.7e-06	2.31e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTEN—hematologic cancer	1.7e-06	2.31e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MDM2—hematologic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CD80—hematologic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CCND1—hematologic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KIT—hematologic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—JUN—hematologic cancer	1.7e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	1.69e-06	2.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3R1—hematologic cancer	1.69e-06	2.28e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—MTHFR—hematologic cancer	1.67e-06	2.26e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	1.67e-06	2.26e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	1.66e-06	2.25e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	1.66e-06	2.24e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MTOR—hematologic cancer	1.66e-06	2.24e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CDKN1A—hematologic cancer	1.64e-06	2.23e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PTEN—hematologic cancer	1.64e-06	2.22e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—EP300—hematologic cancer	1.64e-06	2.22e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK3—hematologic cancer	1.64e-06	2.22e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	1.64e-06	2.22e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—CREBBP—hematologic cancer	1.63e-06	2.21e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	1.63e-06	2.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	1.63e-06	2.2e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—EP300—hematologic cancer	1.62e-06	2.2e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	1.62e-06	2.19e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	1.62e-06	2.19e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	1.62e-06	2.19e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	1.61e-06	2.18e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	1.61e-06	2.18e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK8—hematologic cancer	1.61e-06	2.17e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—AKT1—hematologic cancer	1.6e-06	2.17e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	1.6e-06	2.16e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—hematologic cancer	1.59e-06	2.16e-05	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	1.59e-06	2.16e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.59e-06	2.16e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TGFB1—hematologic cancer	1.59e-06	2.15e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTEN—hematologic cancer	1.59e-06	2.15e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	1.58e-06	2.14e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL2—hematologic cancer	1.57e-06	2.13e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	1.57e-06	2.13e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	1.57e-06	2.13e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	1.57e-06	2.12e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EP300—hematologic cancer	1.57e-06	2.12e-05	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—AKT1—hematologic cancer	1.56e-06	2.12e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CB—hematologic cancer	1.56e-06	2.11e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	1.55e-06	2.1e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CD—hematologic cancer	1.55e-06	2.09e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	1.54e-06	2.08e-05	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	1.54e-06	2.08e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	1.54e-06	2.08e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—JUN—hematologic cancer	1.53e-06	2.08e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ALB—hematologic cancer	1.53e-06	2.07e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CASP3—hematologic cancer	1.52e-06	2.06e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—SRC—hematologic cancer	1.52e-06	2.06e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL2—hematologic cancer	1.52e-06	2.06e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	1.52e-06	2.05e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—EP300—hematologic cancer	1.51e-06	2.05e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL6—hematologic cancer	1.51e-06	2.05e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	1.51e-06	2.04e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	1.5e-06	2.04e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	1.49e-06	2.02e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	1.49e-06	2.01e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—VEGFA—hematologic cancer	1.48e-06	2.01e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCND1—hematologic cancer	1.48e-06	2.01e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	1.48e-06	2.01e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	1.48e-06	2e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—JUN—hematologic cancer	1.48e-06	2e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.48e-06	2e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	1.47e-06	2e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KRAS—hematologic cancer	1.47e-06	1.99e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—STAT3—hematologic cancer	1.47e-06	1.99e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NRAS—hematologic cancer	1.46e-06	1.98e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	1.46e-06	1.98e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	1.46e-06	1.98e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3R1—hematologic cancer	1.46e-06	1.98e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	1.45e-06	1.96e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	1.45e-06	1.96e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL2—hematologic cancer	1.45e-06	1.96e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	1.45e-06	1.96e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.44e-06	1.96e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	1.44e-06	1.95e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	1.44e-06	1.95e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	1.43e-06	1.94e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTEN—hematologic cancer	1.43e-06	1.94e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	1.43e-06	1.94e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EP300—hematologic cancer	1.41e-06	1.91e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	1.41e-06	1.91e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	1.41e-06	1.91e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—JUN—hematologic cancer	1.41e-06	1.91e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.4e-06	1.9e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	1.4e-06	1.9e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	1.4e-06	1.9e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	1.4e-06	1.9e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	1.4e-06	1.9e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	1.4e-06	1.89e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—SRC—hematologic cancer	1.37e-06	1.86e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	1.37e-06	1.86e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	1.37e-06	1.85e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EP300—hematologic cancer	1.36e-06	1.85e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—hematologic cancer	1.36e-06	1.85e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	1.36e-06	1.85e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	1.36e-06	1.84e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	1.35e-06	1.83e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CB—hematologic cancer	1.35e-06	1.82e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTEN—hematologic cancer	1.34e-06	1.82e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	1.34e-06	1.82e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	1.34e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	1.34e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	1.34e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	1.33e-06	1.81e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	1.33e-06	1.8e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—SRC—hematologic cancer	1.33e-06	1.8e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	1.33e-06	1.8e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	1.32e-06	1.79e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	1.31e-06	1.78e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—hematologic cancer	1.31e-06	1.77e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CREBBP—hematologic cancer	1.3e-06	1.76e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	1.3e-06	1.76e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	1.3e-06	1.76e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	1.3e-06	1.76e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EP300—hematologic cancer	1.3e-06	1.76e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	1.29e-06	1.75e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	1.29e-06	1.74e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL2—hematologic cancer	1.29e-06	1.74e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—EP300—hematologic cancer	1.28e-06	1.74e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	1.28e-06	1.73e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—STAT3—hematologic cancer	1.28e-06	1.73e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NRAS—hematologic cancer	1.28e-06	1.73e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	1.27e-06	1.72e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—SRC—hematologic cancer	1.26e-06	1.71e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	1.26e-06	1.71e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	1.25e-06	1.7e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—HRAS—hematologic cancer	1.25e-06	1.7e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—JUN—hematologic cancer	1.25e-06	1.69e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	1.24e-06	1.68e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.23e-06	1.67e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—hematologic cancer	1.23e-06	1.67e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	1.23e-06	1.67e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	1.23e-06	1.66e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	1.22e-06	1.66e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	1.22e-06	1.65e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ALB—hematologic cancer	1.22e-06	1.65e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	1.22e-06	1.65e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	1.22e-06	1.65e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PIK3CA—hematologic cancer	1.21e-06	1.64e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	1.21e-06	1.64e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	1.21e-06	1.64e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	1.21e-06	1.64e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PIK3CA—hematologic cancer	1.2e-06	1.63e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL6—hematologic cancer	1.2e-06	1.62e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.2e-06	1.62e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.19e-06	1.62e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.19e-06	1.61e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.19e-06	1.61e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.19e-06	1.61e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.18e-06	1.6e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.18e-06	1.6e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.17e-06	1.58e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.16e-06	1.58e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTEN—hematologic cancer	1.16e-06	1.58e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	1.16e-06	1.58e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.16e-06	1.57e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	1.16e-06	1.57e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.15e-06	1.56e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.14e-06	1.54e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—hematologic cancer	1.13e-06	1.53e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	1.13e-06	1.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.13e-06	1.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.12e-06	1.52e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.12e-06	1.52e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—hematologic cancer	1.12e-06	1.52e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CA—hematologic cancer	1.12e-06	1.52e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—EP300—hematologic cancer	1.11e-06	1.5e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—AKT1—hematologic cancer	1.11e-06	1.5e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.1e-06	1.49e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.1e-06	1.49e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.1e-06	1.49e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.09e-06	1.48e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.08e-06	1.47e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.08e-06	1.46e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.08e-06	1.46e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.07e-06	1.45e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	1.07e-06	1.45e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	1.05e-06	1.42e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.05e-06	1.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.04e-06	1.41e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.03e-06	1.4e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL6—hematologic cancer	1.03e-06	1.39e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.02e-06	1.38e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.01e-06	1.37e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.01e-06	1.37e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.01e-06	1.36e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.01e-06	1.36e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1e-06	1.36e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1e-06	1.36e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—AKT1—hematologic cancer	9.91e-07	1.34e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—AKT1—hematologic cancer	9.81e-07	1.33e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—hematologic cancer	9.76e-07	1.32e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	9.67e-07	1.31e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	9.61e-07	1.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	9.61e-07	1.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CA—hematologic cancer	9.48e-07	1.28e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	9.46e-07	1.28e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—hematologic cancer	9.34e-07	1.27e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HRAS—hematologic cancer	9.34e-07	1.26e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	9.32e-07	1.26e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTEN—hematologic cancer	9.3e-07	1.26e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—hematologic cancer	9.3e-07	1.26e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	9.29e-07	1.26e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL6—hematologic cancer	9.26e-07	1.25e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—AKT1—hematologic cancer	9.14e-07	1.24e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL6—hematologic cancer	8.94e-07	1.21e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	8.89e-07	1.2e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—EP300—hematologic cancer	8.87e-07	1.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	8.63e-07	1.17e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	8.54e-07	1.16e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	8.54e-07	1.16e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL6—hematologic cancer	8.51e-07	1.15e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—hematologic cancer	8.26e-07	1.12e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AKT1—hematologic cancer	8.24e-07	1.12e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CA—hematologic cancer	8.21e-07	1.11e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	7.93e-07	1.07e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	7.9e-07	1.07e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	7.85e-07	1.06e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—AKT1—hematologic cancer	7.75e-07	1.05e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—hematologic cancer	7.67e-07	1.04e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6—hematologic cancer	7.56e-07	1.02e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	7.34e-07	9.94e-06	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6—hematologic cancer	7.02e-07	9.51e-06	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	6.97e-07	9.45e-06	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—AKT1—hematologic cancer	6.71e-07	9.09e-06	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CA—hematologic cancer	6.56e-07	8.88e-06	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	6.48e-07	8.78e-06	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—AKT1—hematologic cancer	5.36e-07	7.26e-06	CbGpPWpGaD
